

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer
subject to Section 16. Form 4 or
Form 5 obligations may
continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Reasons Bryan M. (Last) (First) (Middle) C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, THIRD FLOOR (Street) BRIDGEWATER, NJ 08807 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Amneal Pharmaceuticals, Inc. [AMRX] 3. Date of Earliest Transaction (MM/DD/YYYY) 5/4/2018	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director _____ 10% Owner <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) CFO 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person ____ Form filed by More than One Reporting Person
---	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	5/4/2018		A		94684	A	(1)	94684	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$9.35	5/4/2018		A		56232		(2)	3/2/2027	Class A Common Stock	56232	(3)	56232	D	
Stock Option	\$33.27	5/4/2018		A		63095		(2)	2/26/2026	Class A Common Stock	63095	(3)	63095	D	
Stock Option	\$40.70	5/4/2018		A		47500		(2)	2/26/2025	Class A Common Stock	47500	(3)	47500	D	
Stock Option	\$25.24	5/4/2018		A		55000		(2)	5/14/2024	Class A Common Stock	55000	(3)	55000	D	
Stock Option	\$17.99	5/4/2018		A		52000		(2)	5/15/2023	Class A Common Stock	52000	(3)	52000	D	
Stock Option	\$15.01	5/7/2018		A		136240		(4)	5/7/2028	Class A Common Stock	136240	\$0.00	136240	D	
Restricted Stock Units	(5)	5/7/2018		A		33311		(6)	(6)	Class A Common Stock	33311	\$0.00	33311	D	

Explanation of Responses:

- Received in exchange for 94,684 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").
- The option is vested and currently exercisable.
- Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock.
- The option vests in four equal annual installments beginning on May 07, 2019.
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Reasons Bryan M. C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD, THIRD FLOOR BRIDGEWATER, NJ 08807			CFO	

Signatures

/s/ Bryan M. Reasons

5/8/2018

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.